Recruiting

3D-printed Biodegradable Breast Implants for Breast Restoration

The purpose of this clinical trial is to evaluate the cosmetic effect of breast reconstruction based on 3D-printed biodegradable material breast implants in personalized breast reconstruction and the quality of life of patients, with traditional breast-conserving surgery and traditional breast reconstruction as controls. It will also explore the safety of breast reconstruction based on 3D-printed biodegradable material breast implants in personalized breast reconstruction. The main question it aims to answer…

ClinicalTrials.gov IDNCT06993714
PhasePHASE2
Enrollment120
SponsorXijing Hospital
Age18 Years
SexFEMALE
I'm interested View official listing

Conditions studied

Breast Cancer, Breast Reconstruction

About this study

The purpose of this clinical trial is to evaluate the cosmetic effect of breast reconstruction based on 3D-printed biodegradable material breast implants in personalized breast reconstruction and the quality of life of patients, with traditional breast-conserving surgery and traditional breast reconstruction as controls. It will also explore the safety of breast reconstruction based on 3D-printed biodegradable material breast implants in personalized breast reconstruction. The main question it aims to answer is: Can breast cancer patients who are not suitable for breast-conserving surgery use 3D-printed biodegradable material breast implants for breast reconstruction? Do patients who undergo breast reconstruction based on 3D-printed biodegradable material breast implants have advantages over those who receive breast-conserving surgery or traditional silicone prosthesis breast reconstruction surgery in terms of cosmetic effects, quality of life and safety? What medical problems may occur when participants use 3D-printed biodegradable material-based breast implants for breast reconstruction? Participants will: Non-random enrollment. In the experimental group, breast reduction surgery based on 3D-printed degradable biological implants was received; In control group 1, traditional breast-conserving surgery was received; Traditional silicone prosthesis breast reconstruction was received in control Group 2.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Female patients with newly diagnosed primary breast cancer, aged 18 to 70 years, confirmed by histopathology. * Willing to undergo breast-conserving surgery, concurrent silicone prosthesis breast reconstruction, or breast reconstruction with 3D-printed biodegradable material breast implants. * Having indications for subcutaneous glandectomy that preserves the nipples and areolas. * ECOG performance status score: 0-1. * If receiving neoadjuvant chemotherapy, the interval between chemotherapy completion and surgery is less than 8 weeks. * Good compliance with the planned treatment, ability to understand the study procedures, and willingness to sign the written informed consent form. Exclusion Criteria: * Age \> 70 years. * Newly diagnosed stage IV metastatic breast cancer. * Multicentric, extensive, or diffuse lesions; or inflammatory breast cancer. * Tumor invasion of the papillary areola complex. * Inability to accept/tolerate radiotherapy. * Breast cancer during pregnancy. * History of other malignant tumors within the past five years (except cured cervical carcinoma in situ and non-melanoma skin cancer). * Abnormal functions of vital organs (heart, lungs, liver, kidneys), poorly controlled diabetes, or other conditions that preclude surgery tolerance. * Patients deemed unsuitable for participation by the researchers.

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.